The Inflation Reduction Act’s Drug Price Negotiation Program will erode only a small portion of global biopharma revenues and is unlikely to cause significant cuts to research and development, find researchers.
Featured Posts
The Swiss pharma’s fourth-quarter sales fell short of analysts’ estimates on Wednesday, as the company said it dropped a late-stage blood cancer hopeful after failing a Phase III study.
Cancer treatment maker 2seventy bio, said it will sell all its experimental cell therapies to Regeneron Pharmaceuticals to focus on its only approved product Abecma.
The biopharma industry has been largely underfunding vaccine development despite its strong potential to prevent diseases and reduce hospitalizations and deaths, according to a report published by industry advocacy group Biotechnology Innovation Organization.
After 26 weeks of follow-up, five of six children treated with an experimental gene therapy developed in China showed strong improvements in speech perception and could hold normal conversations.
In a Phase I/II trial, an 11-year-old boy gradually regained hearing—eventually reaching normal range for some frequencies at 30 days—following treatment with Eli Lilly’s dual adeno-associated viral vector-delivered gene therapy.
The collaboration is focused on the evaluation of Vivtex’s unique and proprietary GI-ORIS™ (“Gut on a chip” and AI) screening and formulation platform technology to support the development of novel, oral versions of a therapeutic candidate provided by Astellas.
While gene therapies for treating sickle cell disease are promising, they will only be cost effective in the U.S. if priced below $2 million, according to a new modeling analysis.
The deal will bolster nthye French company’s drug development portfolio with an experimental treatment for a rare genetic disease.
The company announced today that the trial failed to show that it significantly improved survival for previously treated patients with advanced non-small cell lung cancer.